Document is current
Any future updates will be listed below
-
Authors
Kurup, Sree
de Mendizabal, Nieves Velez
Becker, Stephan
Bolella, Erica
De Sousa, Dorothy
Fätkenheuer, Gerd
Gruell, Henning
Klein, Florian
Malin, Jakob J
Schmid, Ulrike
Korell, Julia
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Deutsches Zentrum für Infektionsforschung
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 14 November 2024
First Online: 5 December 2024
Declarations
:
: SK, EB, DDS, US and JK were all full-time employees of Boehringer Ingelheim when the study analysis was conducted. NVDM was an employee of Metrum Research Group at the time of this analysis. HG, FK, and SB are inventors on patent applications on neutralizing antibodies and have received payments from the University of Cologne and the Philipps University of Marburg for licensed antibodies. NVM is an employee of Gilead and former employee of Metrum Research Group.
: All patients enrolled in the clinical trials provided written informed consent to participate. No identifying information for individual patients is included in this article.
